News >

Immunotherapy Combinations Emerging in NSCLC

Angelica Welch
Published: Saturday, Mar 24, 2018

Chad Pecot, MD

Chad Pecot, MD
Immunotherapy has already carved out a place for itself in the treatment landscape of non–small cell lung cancer (NSCLC), but a wave of new combination therapies is imminent, says Chad Pecot, MD.

State of the Science Summit™ on Non–Small Cell Lung Cancer. In an interview during the meeting, he shared his insight on current clinical trials of immunotherapy combinations in NSCLC.

OncLive: Can you please provide an overview of you talk?

Pecot: I spoke about immunotherapy combinations in lung cancer. There are quite a few different combinations being tested, and there are some emerging data with these combinations. I discussed the combinations that we have data for, and the few caveats and warnings. Then I discussed some clinical trials that are about to launch that are exciting.

What combinations are there currently data for?

We have several different types of combinations. Ones that I discussed were chemotherapy plus immunotherapy, and some of those trials looked good and did work. Some are showing early signs of promise, but it is a little too early. There is a very recent trial, IMpower150, which was presented in Europe a few months ago and looks promising. There are also immunotherapy combinations with various immune agents together, such as nivolumab plus ipilimumab, as well as IDO inhibitors plus immunotherapy. 

Can you highlight some of the success with these combinations?

The IDO inhibitors plus nivolumab or IDO inhibitors plus pembrolizumab (Keytruda)—both of those combinations were presented at the 2017 ASCO Annual Meeting. There are a couple successes there. One is that the response rates were higher than historical rates. We are now looking at 40% to 50% response rates with those combinations. What is exciting is that there did not seem to be any added toxicities. That implies that we can combine even more agents together to perhaps move that response rate even higher. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x